IDEXX Raises 2026 EPS Guidance Amid Q3 Revenue Beat
IDEXX Laboratories reported strong third quarter earnings and raised its 2026 financial outlook, citing double-digit growth in recurring diagnostics revenue and strong commercial execution.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed